Compass Pathways Plc (CMPS)
NASDAQ:CMPS
Want to see CMPS full AI Analyst Report?
Top Page
COMPASS Pathways
(NASDAQ:CMPS)
Select Model
Select Model
Rating:52Neutral
Price Target:
$9.00
▲(35.14% Upside)
Action:ReiteratedDate:04/23/26
The score is primarily held down by weak financial performance (no revenue, escalating losses and cash burn, and negative equity in TTM). Offsetting this are constructive technical momentum and meaningful positive corporate updates (Phase 3 success and improved funding runway), though valuation remains constrained by ongoing unprofitability.
Positive Factors
Phase 3 clinical success
Two Phase 3 trials (COMP005 and COMP006) met primary endpoints showing rapid onset and durable responses out to 26 weeks for a meaningful subset. This materially strengthens regulatory engagement prospects and supports a pathway to potential approval and long‑term commercial opportunity.
Negative Factors
No commercial revenue
The company reports no revenue across periods while net losses widened to roughly $288M TTM. Without a commercial revenue base, Compass remains unable to self‑fund operations, increasing dependence on external capital and exposing the business model to execution and funding risks.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 clinical success
Two Phase 3 trials (COMP005 and COMP006) met primary endpoints showing rapid onset and durable responses out to 26 weeks for a meaningful subset. This materially strengthens regulatory engagement prospects and supports a pathway to potential approval and long‑term commercial opportunity.
Read all positive factors
COMPASS Pathways (CMPS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$952.21M
Dividend YieldN/A
Average Volume (3M)2.22M
Price to Earnings (P/E)―
Beta (1Y)1.54
Revenue GrowthN/A
EPS Growth-32.72%
CountryUS
Employees166
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-3.05
Shares Outstanding134,923,300
10 Day Avg. Volume2,381,107
30 Day Avg. Volume2,222,570
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-12.21
Price to Sales (P/S)0.00
P/FCF Ratio-4.10
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-139.82K
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$22.67Price Target Upside240.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-1.8
Revenue Forecast (FY)$3.00M
COMPASS Pathways Business Overview & Revenue Model
Company Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant de...
How the Company Makes Money
null...
COMPASS Pathways Earnings Call Summary
Earnings Call Date:Nov 04, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook with significant progress in clinical trials, regulatory interactions, and launch preparations. While there was a decrease in cash reserves, the company maintains a strong cash position with a runway into 2027.Positive Updates
Acceleration of Launch Plans
COMPASS Pathways announced a 9- to 12-month acceleration of their launch plans for COMP360, highlighting excellent progress.
Negative Updates
Cash Decrease
Cash and cash equivalents decreased from $222 million at the end of the second quarter to $186 million at the end of September.
Read all updates
Q3-2025 Updates
Positive
Negative
Acceleration of Launch Plans
COMPASS Pathways announced a 9- to 12-month acceleration of their launch plans for COMP360, highlighting excellent progress.
Read all positive updates
Company Guidance
During the COMPASS Pathways Third Quarter 2025 Earnings Call, the company announced significant advancements, including a potential 9- to 12-month acceleration of their launch plans for COMP360. The first Phase III trial, COMP005, demonstrated highly statistically significant results for the primary endpoint, contributing to an accelerated NDA filing timeline with the FDA, potentially through a rolling submission. The company completed enrollment for the second Phase III trial, COMP006, with 26-week data expected in early Q3 2026. Financially, COMPASS reported $186 million in cash and cash equivalents at the end of September 2025, with a disciplined spending plan maintaining their cash runway into 2027. The company is pulling forward commercial preparations, focusing on strategic collaborations and understanding provider sentiment, aiming to integrate COMP360 into the growing interventional psychiatry infrastructure effectively.COMPASS Pathways Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
28
Negative
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -216.50K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -179.04M | -148.82M | -115.24M | -90.77M | -71.37M |
| Net Income | -287.86M | -155.12M | -118.46M | -91.50M | -71.74M |
Balance Sheet | |||||
| Total Assets | 210.35M | 213.67M | 275.99M | 197.29M | 300.90M |
| Cash, Cash Equivalents and Short-Term Investments | 149.61M | 165.08M | 220.20M | 143.21M | 273.24M |
| Total Debt | 20.93M | 32.19M | 33.05M | 1.93M | 3.61M |
| Total Liabilities | 263.20M | 58.97M | 50.24M | 16.01M | 16.49M |
| Stockholders Equity | -52.85M | 154.69M | 225.74M | 181.28M | 284.41M |
Cash Flow | |||||
| Free Cash Flow | -157.24M | -119.19M | -97.44M | -106.05M | -68.08M |
| Operating Cash Flow | -157.24M | -119.19M | -97.38M | -105.45M | -67.75M |
| Investing Cash Flow | 0.00 | 0.00 | -64.00K | -596.00K | -334.00K |
| Financing Cash Flow | 140.71M | 63.82M | 173.83M | 1.04M | 156.65M |
COMPASS Pathways Technical Analysis
Positive
6.66
Price Trends
6.38
Positive
6.46
Positive
5.78
Positive
Market Momentum
-0.02
Negative
61.96
Neutral
90.31
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMPS, the sentiment is Positive. The current price of 6.66 is above the 20-day moving average (MA) of 5.69, above the 50-day MA of 6.38, and above the 200-day MA of 5.78, indicating a bullish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 61.96 is Neutral, neither overbought nor oversold. The STOCH value of 90.31 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CMPS.
COMPASS Pathways Risk Analysis
COMPASS Pathways disclosed 100 risk factors in its most recent earnings report. COMPASS Pathways reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
COMPASS Pathways Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $869.39M | 32.08 | 6.89% | ― | 22.00% | 589.71% | |
60 Neutral | $425.96M | -17.34 | -27.10% | ― | -20.37% | -479.68% | |
56 Neutral | $904.76M | 1.10 | -146.01% | ― | -2.82% | -45.70% | |
54 Neutral | $399.93M | -313.53 | 326.77% | ― | 35.37% | 46.10% | |
54 Neutral | $1.03B | -9.24 | -9.20% | ― | 14.13% | 62.92% | |
52 Neutral | $952.21M | -2.24 | -335.93% | ― | ― | -32.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
CMPS
COMPASS Pathways
9.65
5.74
146.80%
CCRN
Cross Country Healthcare
13.12
-0.80
-5.75%
TOI
Oncology Institute
4.01
1.46
57.25%
TALK
Talkspace
5.19
2.11
68.51%
INNV
InnovAge Holding
7.36
3.56
93.68%
AGL
Agilon Health
59.61
-14.64
-19.72%
COMPASS Pathways Corporate Events
Business Operations and StrategyPrivate Placements and Financing
COMPASS Pathways Announces $150 Million Public Offering
Positive
Feb 19, 2026
On February 18, 2026, Compass Pathways priced an underwritten public offering of 17.5 million American Depositary Shares at $8.00 each and pre-funded warrants for 1.25 million ADSs at $7.9999, with underwriters granted a 30-day option to buy up to...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
COMPASS Pathways Reports Positive Phase 3 Results in TRD
Positive
Feb 17, 2026
On February 17, 2026, COMPASS Pathways reported that its second Phase 3 trial, COMP006, met its primary endpoint, with two 25 mg doses of COMP360 psilocybin given three weeks apart showing a highly statistically significant and clinically meaningf...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.